S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
NASDAQ:DAWN

Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

$14.61
+0.76 (+5.49%)
(As of 04/16/2024 ET)
Today's Range
$13.80
$14.73
50-Day Range
$13.77
$17.46
52-Week Range
$9.67
$17.85
Volume
751,033 shs
Average Volume
616,041 shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.60

Day One Biopharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
177.9% Upside
$40.60 Price Target
Short Interest
Bearish
15.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Day One Biopharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$722,960 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.66) to ($2.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

576th out of 930 stocks

Pharmaceutical Preparations Industry

256th out of 408 stocks

DAWN stock logo

About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DAWN Stock Price History

DAWN Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Day One Biopharmaceuticals Inc DAWN
DAWN Jul 2024 17.500 call
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals Inc
See More Headlines
Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/17/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DAWN
Fax
N/A
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.60
High Stock Price Target
$50.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+177.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-188,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.98 per share

Miscellaneous

Free Float
80,037,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
-1.48
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Jeremy Bender M.B.A. (Age 53)
    Ph.D., CEO, President & Director
    Comp: $900k
  • Dr. Samuel C. Blackman M.D. (Age 55)
    Ph.D., Co-Founder and Head of R&D
    Comp: $651k
  • Mr. Charles N. York II (Age 47)
    COO, CFO & Secretary
    Comp: $715k
  • Dr. Mike Preigh Ph.D.
    Chief of Technology Operations
  • Mr. Adam Dubow (Age 57)
    General Counsel
  • Ms. Jaa Roberson
    Chief People Officer
  • Dr. Davy Chiodin Ph.D.
    Pharm.D., Chief Development Officer
  • Ms. Lauren Merendino M.B.A. (Age 48)
    Chief Commercial Officer
  • Dr. Elly Barry M.D.
    Chief Medical Officer

DAWN Stock Analysis - Frequently Asked Questions

Should I buy or sell Day One Biopharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DAWN shares.
View DAWN analyst ratings
or view top-rated stocks.

What is Day One Biopharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price targets for Day One Biopharmaceuticals' shares. Their DAWN share price targets range from $34.00 to $50.00. On average, they expect the company's stock price to reach $40.60 in the next twelve months. This suggests a possible upside of 177.9% from the stock's current price.
View analysts price targets for DAWN
or view top-rated stocks among Wall Street analysts.

How have DAWN shares performed in 2024?

Day One Biopharmaceuticals' stock was trading at $14.60 at the start of the year. Since then, DAWN stock has increased by 0.1% and is now trading at $14.61.
View the best growth stocks for 2024 here
.

Are investors shorting Day One Biopharmaceuticals?

Day One Biopharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 8,980,000 shares, a decrease of 6.6% from the March 15th total of 9,610,000 shares. Based on an average daily volume of 619,200 shares, the short-interest ratio is presently 14.5 days. Currently, 15.2% of the company's stock are short sold.
View Day One Biopharmaceuticals' Short Interest
.

When is Day One Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our DAWN earnings forecast
.

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) posted its quarterly earnings results on Monday, February, 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.07.

What ETFs hold Day One Biopharmaceuticals' stock?

ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).ALPS Medical Breakthroughs ETF (SBIO).

When did Day One Biopharmaceuticals IPO?

Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DAWN) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners